RENEWCELL

PRESS RELEASE 30 June 2023 00:45:00 CEST

Renewcell completes a directed issue of 3,333,333 new shares to Swedish and international institutional investors, raising gross proceeds of approximately SEK 240 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.

The Board of Directors of Re:NewCell AB (publ) ("Renewcell" or the "Company") has, based on the authorization granted by the annual general meeting held on 16 May 2023 and with deviation from the shareholders' preferential right, resolved to carry out a directed share issue of 3,333,333 new shares at a subscription price of SEK 72 per share to Swedish and International institutional investors (the "Directed Share Issue"). The subscription price was determined through an accelerated book-building procedure performed by Nordea Bank Abp, filial i Sverige ("Nordea") and Pareto Securities AB ("Pareto" and together with Nordea, the "Managers"). The Directed Share Issue was subscribed by a number of Swedish and international institutional investors and existing shareholders, H&M Group, Girincubator AB (via the family affiliated Girindus Investments AB), Handelsbanken Fonder, AMF Fonder and Storebrand Fonder among others.

The bookbuilding procedure which was announced by the Company earlier today has been completed. The Board of Directors of Renewcell has decided to carry out a directed issue of 3,333,333 new shares, at a subscription price of SEK 72 per share, consequently raising proceeds of approximately SEK 240 million before transaction costs.

The proceeds from the Directed Share Issue will mainly be used to finance operational expenses during a longer rampup of production (partly due to the fire in March 2023), additional working capital requirements and increased capital expenditures ("CAPEX"). It is the Board of Directors' assessment that the Directed Share Issue covers the Company's funding need, without the need for additional equity, to complete the production ramp-up of Renewcell 1 to 60,000 tonnes in the first stage and then to 120,000 tonnes in a later stage. The assessment takes into account the delayed start-up and slower than expected production ramp-up, provided that no further unexpected negative events occur such as lengthy production stops, technical production limitations or other similar events.

Due to the Directed Share Issue, the number of shares and votes in the Company will increase by 3,333,333 from 37,366,216 to 40,699,549. The Directed Share Issue entails a dilution of approximately 8.2 percent of the number of shares and votes in the Company (calculated as the number of newly issued shares divided by the total number of shares in the Company after the Directed Share Issue). The share capital will increase by SEK 85,074.77 from SEK 953,676.70 to SEK 1,038,751.47.

Prior to the Directed Share Issue, the Board of Directors has also considered the possibility to raise the required equity through a rights issue but concluded that a rights issue would be significantly more time-consuming and entail significantly higher costs and increased exposure to potential market volatility compared to the Directed Share Issue. Given the market volatility seen during 2022, that is still ongoing during 2023, the Board of Directors has assessed that a rights issue would also require a rather significant underwriting from a guarantor syndicate that would entail additional costs and/or additional dilution depending on the type of remuneration for such underwriting. The more time-consuming rights issue alternative would also further delay the production ramp-up of Renewcell 1 to 60,000 tonnes in the first stage and then to 120,000 tonnes in a later stage, which in turn would lead to a corresponding delay of revenue generation that may cause a further need for external funding. The Company has concluded that a delayed ramp-up is not in the best interest of the shareholders. Unlike a rights issue, the Directed Share Issue can also broaden as well as strengthen the shareholder base and provide the Company with new shareholders, which the Board of Directors considers to be of great benefit to Renewcell.

In the light of the above, the Board of Directors made the assessment that a Directed Share Issue with deviation from the shareholders' preferential rights was the most favourable alternative for Renewcell and in the best interest of all the Company's shareholders. As the subscription price in the Directed Share Issue was determined through a bookbuilding procedure at arm's length, the Board of Directors assesses that the subscription price reflects current market value and demand.

Extension of revolving credit facility

The company holds a so-called revolving credit facility ("RCF") of SEK 150 million issued by a bank syndicate consisting of Nordea, BNP Paribas and Svensk Exportkredit (SEK). The RCF, which the Company has fully drawn, was originally due in October 2023 but has now been extended on original terms, initially to April 2024. After the end of the first quarter of 2023, another RCF of SEK 75 million was issued to the Company by the same bank syndicate (the "New RCF"), which gives the Company a total available amount under the RCF and the New RCF of SEK 225 million. As of today, the Company has drawn SEK 37.5 million of the New RCF. The drawn amount under the New RCF shall be repaid in October 2023 or when the Company carries out a new issue, depending on which of these events occurs first. Following the Directed Share Issue, the bank syndicate has agreed to extend the period for repayment of the drawn amount under the New RCF subject to certain conditions, including the Company receiving the desired gross proceeds in the Directed Share Issue.

Lock-up

The Company has, subject to certain exemptions, undertaken, in favour of the Managers, not to issue additional shares for a period of 180 calendar days from the settlement date of the Directed Share Issue.

Advisors

In conjunction with the Directed Share Issue, the Company has engaged Nordea as Sole Global Coordinator and Joint Bookrunner and Pareto as Joint Bookrunner. Advokatfirman Vinge KB is legal advisor to the Company and Baker & McKenzie Advokatbyrå KB is legal advisor to the Sole Global Coordinator and Joint Bookrunners.

Contacts

Patrik Lundström
CEO
patrik.lundstrom@renewcell.com
+46 76 183 47 17

Toby Lawton
CFO
toby.lawton@renewcell.com
+46 70 242 29 47

About Renewcell

Founded by innovators from Stockholm's KTH Royal Institute of Technology in 2012, Re:NewCell AB (publ) ("Renewcell") is a multi-award-winning sustaintech company based in Sweden. The company's vision is to make fashion circular.

Through its patented process, Renewcell is able to recycle cellulosic textile waste, such as worn-out cotton clothes and production scraps, transforming it into a pristine new material called CIRCULOSE®. Fast Company named Renewcell one of the World's Most Innovative Companies in 2021 and CIRCULOSE® was also included on TIME Magazine's list of the 100 Best Inventions 2020.

Renewcell is a publicly listed company with shares traded on Nasdaq First North Premier Growth Market with the ticker name RENEW and ISIN code SE0014960431. FNCA Sweden AB is Certified Adviser, +46(0)8-528 00 399, info@fnca.se.

This information constitute inside information that Re:NewCell AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-06-30 00:45 CEST.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions by law. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer to sell or an offer, or the solicitation of an offer, to acquire or subscribe for shares issued by the Company in any jurisdiction where such offer or invitation would be illegal prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction. This press release is not a prospectus for the purposes of the Prospectus Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. The Company has not authorized any offer to the public of shares or

rights in any Member State of the EEA and no prospectus has been or will be prepared in connection with the Directed Share Issue. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); (ii) high net worth entities etc. falling within Article 49 (2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the new shares. Any investment decision to acquire or subscribe for shares in connection with the Directed Share Issue must be made on the basis of all publicly available information relating to the Company and the Company's shares. Such information has not been independently verified by the Managers. The Managers are acting for the Company in connection with the transaction and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the transaction or any other matter referred to herein.

The information in this press release may not be forwarded or distributed to any other person and may not be reproduced at all. Any forwarding, distribution, reproduction or disclosure of this information in its entirety or in any part is prohibited. Failure to follow these instructions may result in a breach of the Securities Act or applicable laws in other jurisdictions.

Re:NewCell AB (publ) Press Release 30 June 2023 00:45:00 CEST

This press release does not constitute an invitation to warrant, subscribe, or otherwise acquire or transfer any securities in any jurisdiction. This press release does not constitute a recommendation for any investors' decisions regarding the Directed Share Issue. Each investor or potential investor should conduct a self-examination, analysis and evaluation of the business and information described in this press release and any publicly available information. The price and value of the securities can decrease as well as increase. Achieved results do not provide guidance for future results. Neither the contents of the Company's website nor any other website accessible through hyperlinks on the Company's website are incorporated into or form part of this press release.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forwardlooking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forwardlooking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is not required by law or Nasdag First North Growth Market Rulebook.

This information is information that Re:NewCell AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-06-30 00:45 CEST.

Attachments

Renewcell completes a directed issue of 3,333,333 new shares to Swedish and international institutional investors, raising gross proceeds of approximately SEK 240 million